Free Trial

Artiva Biotherapeutics (ARTV) News Today

Artiva Biotherapeutics logo
$3.06 -0.11 (-3.32%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
HC Wainwright Analysts Boost Earnings Estimates for ARTV
Artiva Biotherapeutics, Inc. stock logo
Equities Analysts Set Expectations for ARTV Q1 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for Artiva Biotherapeutics in a report released on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will earn ($0.68) per sha
Cantor Fitzgerald Brokers Reduce Earnings Estimates for ARTV
Artiva Biotherapeutics stock rises following analyst optimism
Artiva Biotherapeutics, Inc. stock logo
Brokers Offer Predictions for ARTV FY2025 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, March 25th. Cantor Fitzgerald analyst J. Schimmer now anticipates
Artiva Biotherapeutics, Inc. stock logo
Analysts Issue Forecasts for ARTV Q1 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush issued their Q1 2025 earnings per share estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Monday, March 24th. Wedbush analyst D. Nierengarten forecasts that the company will p
Artiva Biotherapeutics, Inc. stock logo
HC Wainwright Reaffirms Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday.
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor Fitzgerald
Cantor Fitzgerald decreased their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday.
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Earns Outperform Rating from Wedbush
Wedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday.
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics' (ARTV) "Buy" Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday.
Artiva Biotherapeutics, Inc. (ARTV) Gets a Buy from TD Cowen
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Brokerages
Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been given an average rating of "Buy" by the six research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The averag
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Tuesday
Artiva Biotherapeutics (NASDAQ:ARTV) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Buy" by the six brokerages that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brok
Artiva Biotherapeutics, Inc. stock logo
Research Analysts Issue Forecasts for ARTV FY2025 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Artiva Biotherapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings pe
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics, Inc.'s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV)
Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its IPO on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the expiration of Artiva Biotherapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Artiva Biotherapeutics, Inc. stock logo
Geode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 308,930 shares of the company's
Artiva Biotherapeutics, Inc. stock logo
State Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
State Street Corp bought a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 86,559 shares of the company's stock, valued at approximately $1,337,000. State
Artiva Biotherapeutics, Inc. stock logo
Research Analysts Issue Forecasts for ARTV FY2024 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - HC Wainwright issued their FY2024 EPS estimates for Artiva Biotherapeutics in a note issued to investors on Monday, December 30th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($6.00) for the
Artiva Biotherapeutics initiated with a Buy at H.C. Wainwright
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC Wainwright
HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research note on Monday. They set a "buy" rating and a $20.00 target price for the company.
Artiva Biotherapeutics, Inc. stock logo
Franklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
Franklin Resources Inc. acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 520,301 shares of the company's stock, valued at approxi
Artiva Biotherapeutics, Inc. stock logo
Wellington Management Group LLP Invests $2.91 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
Wellington Management Group LLP bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 194,108 shares of the compa
Artiva Biotherapeutics, Inc. stock logo
Samsara BioCapital LLC Acquires New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 291,666 shares of the company's stock, valued at approx
Artiva Biotherapeutics, Inc. stock logo
RA Capital Management L.P. Takes $152.23 Million Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
RA Capital Management L.P. bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,853,302 shares of the company's stock, valued at approximately $152,234,000.
Artiva Biotherapeutics, Inc. stock logo
RTW Investments LP Takes $2.30 Million Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
RTW Investments LP bought a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 148,844 shares of the company's stock, valued at approximately $
Artiva Biotherapeutics, Inc. stock logo
Acuta Capital Partners LLC Takes $680,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 44,000 shares of the company's
Artiva Biotherapeutics, Inc. stock logo
Cantor Fitzgerald Forecasts ARTV FY2024 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects tha
Artiva Biotherapeutics, Inc. stock logo
Wedbush Has Bearish Forecast for ARTV FY2024 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush cut their FY2024 earnings per share estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Announces Earnings Results
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24).
Artiva Biotherapeutics, Inc. stock logo
Needham & Company LLC Reiterates "Buy" Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday.
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD Cowen
Remove Ads
Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.

ARTV Media Mentions By Week

ARTV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARTV
News Sentiment

0.32

0.82

Average
Medical
News Sentiment

ARTV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARTV Articles
This Week

33

2

ARTV Articles
Average Week

Remove Ads
Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ARTV) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners